close :

:

Forgotten your password?
 
New Drug Applications
Printable Version   Email to a friend

Macugen

pegaptanib

Treatment for Macular Degeneration

FDA Announces Advisory Committee Meeting Date for Macugen (pegaptanib sodium injection)

NEW YORK, May 26, 2004 -- Eyetech Pharmaceuticals, Inc. (Nasdaq: EYET) a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye, has learned today that the Food and Drug Administration has announced the forthcoming meeting of a public advisory committee of the FDA to discuss the new drug application 21-756, pegaptanib sodium injection (proposed trade name, Macugen) by Eyetech Pharmaceuticals, Inc., indicated for the treatment of exudative (wet) age-related macular degeneration to be held on August 27, 2004 at 8:00 AM EDT at FDA in Rockville, Maryland.

About Eyetech Pharmaceuticals, Inc.
Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye. Eyetech's initial focus is on diseases affecting the back of the eye. The company's most advanced product candidate is Macugen (pegaptanib sodium injection), which Eyetech is developing with Pfizer Inc for the prevention and treatment of diseases of the eye and related conditions. Eyetech's lead clinical trials include two phase 2/3 pivotal clinical trials for the use of Macugen in the treatment of the wet form of age-related macular degeneration and a phase 2 clinical trial for the use of Macugen for the treatment of diabetic macular edema.

For further information, please visit www.eyetech.com

SOURCE Eyetech Pharmaceuticals, Inc.

Related Articles:

Macugen Eyetech / Pfizer Inc - Treatment for Neovascular (Wet) Age-Related Macular Degeneration - December 17, 2004

FDA Advisory Committee Reviews Clinical Data of Eyetech/Pfizer Priority 1 NDA Submission for Macugen, an Investigational Treatment for Neovascular AMD - August 27, 2004

Eyetech/Pfizer Announce FDA Acceptance of the New Drug Application for Macugen (pegaptanib sodium injection) - August 18, 2004

Eyetech/Pfizer File New Drug Application for Macugen (pegaptanib sodium injection), the First Investigational Anti-VEGF Therapy for Wet Age-Related Macular Degeneration - June 17, 2004

Latest New Drug Applications...

New Drug Applications Archive

2008: Jan | Feb | Mar | Apr | May
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec

More News Resources


Join Drugs.com
Click here to see what benefits you can get by joining our FREE membership programme.
Drugs.com is the most popular, comprehensive, and up-to-date source of drug information online. Providing advice on more than 24,000 prescription drugs and over-the-counter medicines for consumers and professionals .
Advertisement
In The Pipeline